Award
NIH Reporter #1UG3AG101657-01
Repurposing a Reverse Transcriptase Inhibitor To Target Retrotransposons and Prevent Alzheimer's Disease in People with Down Syndrome: A Two-Phase UG3/UH3 Clinical Drug Development Program
Recipient
Not specified
Award Amount
$1,478,201.00
Ceiling
$1,478,201.00
Awarded
August 06, 2026
Identifier
1UG3AG101657-01
Award for a clinical drug development program to repurpose a reverse transcriptase inhibitor to prevent Alzheimer's disease in people with Down syndrome.
Description
This project involves clinical trials to evaluate the safety and efficacy of lamivudine in preventing Alzheimer's disease in individuals with Down syndrome, with a focus on neuroinflammation and biomarkers.